News from novartis A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

Aug 02, 2018, 07:00 ET Novartis announces US renewables agreement to reduce greenhouse gas emissions

Novartis announced today a Virtual Power Purchase Agreement (VPPA) in collaboration with Invenergy, North America's largest privately held renewable...


Jul 20, 2018, 09:05 ET Alcon introduces NGENUITY® 3D Visualization System with DATAFUSION™ to simplify, customize vitreoretinal surgery

Alcon, the global leader in eye care and a division of Novartis, launches the new NGENUITY 3D Visualization System with DATAFUSION at the 2018...


Jun 27, 2018, 07:30 ET Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community

Novartis today announced support for three US-based patient advocacy groups provided through the STEP (Solutions to Empower Patients)TM Program. The...


Jun 27, 2018, 04:30 ET Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month

Novartis and the European Migraine and Headache Alliance today announced initial findings from a large global migraine patient survey, involving more ...


Jun 16, 2018, 05:37 ET Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

Novartis today announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah®...


Jun 07, 2018, 09:54 ET Acesso à tratamento para pacientes com doença sanguínea poderá ser ampliado na saúde pública (SUS)

A Comissão Nacional de Incorporação de Tecnologias no SUS (CONITEC) acaba de abrir Consulta Pública para avaliar a inclusão de eltrombopague olamina...


Jun 03, 2018, 09:05 ET Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Novartis today announced positive results from the third Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer....


Jun 02, 2018, 04:01 ET New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

New Novartis data from two long-term Treatment-free Remission (TFR) studies in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid...


May 28, 2018, 10:34 ET Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

Novartis announced today new real world evidence from the CHAMP-HF registry comparing Entresto® (sacubitril/valsartan) patients to patients not...


May 17, 2018, 07:11 ET Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention

Novartis today announced that the US Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive treatment of...


May 07, 2018, 01:15 ET Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally

Alcon, the global leader in eye care and a division of Novartis, today announced Alcon Cares Project 100, which aims to reduce cataract blindness by...


May 01, 2018, 04:41 ET Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for...


Apr 30, 2018, 04:29 ET Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma

Novartis announced today that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist®...


Apr 30, 2018, 04:07 ET New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval

Novartis announced new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (nAMD) from a pre-specified secondary...


Apr 25, 2018, 01:16 ET Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home

Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow...


Apr 13, 2018, 04:15 ET Alcon introduces pre-loaded delivery system for the CyPass® Micro-Stent to enhance surgical experience

Alcon, the global leader in eye care and a division of Novartis, launches the CyPass Ultra System designed to streamline the process of loading the...


Apr 10, 2018, 07:50 ET Novartis drug Afinitor DISPERZ® receives FDA approval to treat TSC-associated partial-onset seizures

Novartis today announced that the US Food and Drug Administration (FDA) has approved Afinitor DISPERZ® (everolimus tablets for oral suspension), for...


Mar 22, 2018, 07:45 ET Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive...


Feb 16, 2018, 04:09 ET Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis

Novartis announced today additional results from the SCULPTURE study showing that two thirds of moderate to severe plaque psoriasis patients treated...


Feb 08, 2018, 01:22 ET Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first...


Jan 31, 2018, 05:09 ET Novartis Announces NEJM Publication Of Updated Analysis From ELIANA Trial Showing Longer-Term Durable Remissions With Kymriah™ In Children, Young Adults With r/r ALL

Novartis today announced updated results from the pivotal ELIANA clinical trial of Kymriah™ (tisagenlecleucel), formerly CTL019, in relapsed or...


Jan 17, 2018, 01:18 ET Novartis granted US FDA Priority Review for Kymriah™ (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL

Novartis today announced that its supplemental Biologics License Application (sBLA) for Kymriah™ (tisagenlecleucel) suspension for intravenous...


Dec 22, 2017, 15:56 ET Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® ...


Dec 22, 2017, 06:30 ET Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma

Novartis announced today the US Food and Drug Administration (FDA) has accepted the Company's supplemental New Drug Application (sNDA) for filing,...


Dec 18, 2017, 08:00 ET Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for fingolimod for the treatment ...